Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.100 AlteredExpression disease BEFREE Suppressor of activator protein-1 regulated by interferon expression in prostate cancer tissues and cells. 31276688 2019
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.100 Biomarker disease BEFREE Correction to: MicroRNA-30d promotes angiogenesis and tumor growth via MYPT1/c-JUN/VEGFA pathway and predicts aggressive outcome in prostate cancer. 31387585 2019
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.100 Biomarker disease BEFREE Finally, we construct a mechanism-based mathematical model that allows us to capture the interactions ofdifferent phosphoforms of PAGE4 with AP-1 and its downstream target, the androgen receptor (AR)-a key therapeutic target in prostate cancer. 29758263 2018
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.100 Biomarker disease BEFREE MicroRNA-30d promotes angiogenesis and tumor growth via MYPT1/c-JUN/VEGFA pathway and predicts aggressive outcome in prostate cancer. 28241827 2017
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.100 Biomarker disease BEFREE Hence, to determine the implication of AR and AP-1 in promoting the transition of prostate cancer to the androgen-independent state, we used AR-positive LNCaP and AR-negative PC-3 cells as an in vitro model system. 28386843 2017
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.100 AlteredExpression disease BEFREE In addition, luciferase reporter gene assay showed that the transcriptional activity of AP-1 and NF-κB in PC-3 and LNCaP prostate carcinoma cell lines was also modulated by the overexpression of EGR-1 in these cells using tandem repeated Luc-AP-1 and Luc-NF-κB. 21617851 2011
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.100 AlteredExpression disease BEFREE These results suggest that Egr-1 may promote prostate cancer development by modulating the activity of factors NF-κB and AP-1, which are involved in cell proliferation and apoptosis. 21743958 2011
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.100 Biomarker disease BEFREE Transcription factor AP-1 promotes growth and radioresistance in prostate cancer cells. 19787273 2009
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.100 Biomarker disease BEFREE Modulation of activator protein-1 (AP-1) and MAPK pathway by flavonoids in human prostate cancer PC3 cells. 16964758 2006
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.100 Biomarker disease BEFREE In the present study, we determined the effects of SFN, PEITC and AITC on AP-1 activation, and investigated the roles of extracellular signal-regulated protein kinase (ERK) and c-Jun N-terminal kinase (JNK) signaling pathways in the regulation of AP-1 activation and cell death elicited by these ITCs in human prostate cancer PC-3 cells. 16272172 2006
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.100 AlteredExpression disease BEFREE Effects of androgen-activated androgen receptor on AP-1 activity were determined in the LNCaP human prostate carcinoma cell model. 15486991 2005
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.100 Biomarker disease BEFREE These results support the notion that HARP is important for human prostate cancer cell proliferation and migration, establish the role of AP-1 in the up-regulation of HARP expression by low concentrations of HP, and characterize the AP-1 dimers involved. 16199533 2005
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.100 Biomarker disease BEFREE Our data demonstrate for the first time that a combined aberrant activation of NF-kappaB p50 and p65 and AP-1 JunD and Fra-1 in androgen-independent prostate cancer cells results in deregulated IL-6 expression, suggesting a novel potential entry point for therapeutic intervention in prostate cancer. 12727841 2003